Who are Lidocaine HCl 0.8% in D5W's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ropivacaine concentration low, Topiramate monotherapy, Bupivacaine low dose, Bupivacaine(B), Bupivacaine supraclavicular block, Anesthetic Topical Adhesive Synera.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lidocaine-hcl-0-8-in-d5w.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Lidocaine HCl 0.8% in D5W — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lidocaine HCl 0.8% in D5W (Lidocaine HCl 0.8% in D5W) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic / Antiarrhythmic (Class IB). Area: Anesthesia / Cardiology.

marketed Local anesthetic / Antiarrhythmic (Class IB) Voltage-gated sodium channels Anesthesia / Cardiology Small molecule Live · refreshed every 30 min

Target snapshot

Lidocaine HCl 0.8% in D5W (Lidocaine HCl 0.8% in D5W) — Vanderbilt University Medical Center. Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lidocaine HCl 0.8% in D5W TARGET	Lidocaine HCl 0.8% in D5W	Vanderbilt University Medical Center	marketed	Local anesthetic / Antiarrhythmic (Class IB)	Voltage-gated sodium channels
Ropivacaine concentration low	Ropivacaine concentration low	Oslo University Hospital	marketed	Local anesthetic	Voltage-gated sodium channels
Topiramate monotherapy	Topiramate monotherapy	Johnson & Johnson Taiwan Ltd	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor; voltage-gated sodium channels
Bupivacaine low dose	Bupivacaine low dose	Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine(B)	Bupivacaine(B)	Huazhong University of Science and Technology	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Bupivacaine supraclavicular block	Bupivacaine supraclavicular block	Jose Soberon, MD	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Anesthetic Topical Adhesive Synera	Anesthetic Topical Adhesive Synera	Brown, Theodore R., M.D., MPH	marketed	Topical local anesthetic	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic / Antiarrhythmic (Class IB) class)

Vanderbilt University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lidocaine HCl 0.8% in D5W — Competitive Intelligence Brief. https://druglandscape.com/ci/lidocaine-hcl-0-8-in-d5w. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab